article
Risk, benefit or cost: What stops patients from receiving a diagnostic test?
Diagnostic tests can help identify disease and disease probability in patients, leading to earlier treatment, but what’s the real cost?
List view / Grid view
Assays
news
Hands-on lateral flow test development workshop
6 June 2017 | By BBI Solutions
BBI Solutions, in partnership with Merck and Kinematic Automation, is hosting a lateral flow seminar designed to provide a practical insight into lateral flow test development...
news
FDA approves Roche’s lung cancer companion diagnostic
6 June 2017 | By Niamh Marriott, Junior Editor
The FDA have approved Roche’s VENTANA ALK (D5F3) CDx Assay as a companion diagnostic to identify ALK-positive non-small cell lung cancer (NSCLC) patients...
news
New entry level reader configurations to simplify basic research
19 May 2017 | By Tecan
Tecan’s popular Infinite® 200 PRO series of multimode microplate readers has been updated to even better serve the life sciences market, with a number of new options and configurations designed to provide flexible and user-friendly solutions for entry level research applications...
news
Roche receives FDA approval for bladder cancer biomarker assay
5 May 2017 | By Niamh Marriott, Junior Editor
The FDA has approved Roche’s biomarker assay as a complementary diagnostic to provide PD-L1 status for patients with urothelial carcinoma...
news
FDA approves Roche’s high-volume immunoassay
4 May 2017 | By Niamh Marriott, Junior Editor
Roche’s new, dedicated high-volume testing immunoassay solution for the cobas 8000 modular analyser series, the cobas e 801 module, has received 510(k) clearance from the US Food and Drug Administration (FDA). As core laboratories continue to evolve to meet the growing workload demands in an increasingly challenging environment, the cobas…
news
FDA approves new combination treatment for acute myeloid leukaemia
4 May 2017 | By Niamh Marriott, Junior Editor
The drug is approved for use in combination with LeukoStrat CDx FLT3 Mutation Assay, which is used to detect the FLT3 mutation in patients with AML...
news
IntelliCyt launches novel assay system to accelerate cell line development
3 April 2017 | By IntelliCyt
The IntelliCyt Cy-Clone™ PLUS Assay System will accelerate and improve the quality of clone ranking and selection for developing cell lines which can reduce production costs of biopharmaceuticals...
news
Biocartis and Merck partnership launch second liquid biopsy assay
15 March 2017 | By Niamh Marriott, Junior Editor
This collaboration is aimed at jointly developing and commercialising new liquid biopsy RAS biomarker tests for metastatic colorectal cancer (mCRC)...
news
FDA approves Roche’s assay to assess ovarian reserve
10 January 2017 | By Niamh Marriott, Digital Editor
The blood test produces standardised results for assessing ovarian reserve as compared with the use of vaginal ultrasound...
news
Biocartis launches second liquid biopsy assay
14 December 2016 | By Niamh Louise Marriott, Digital Editor
Biocartis launched its second liquid biopsy assay, the Idylla ctKRAS Mutation Assay, which was developed in partnership with Merck...
whitepaper
Quantification of Tablets Containing Multiple APIs: Using Transmission Raman
The ability to predict multiple constituents of a final dosage form in one fast, non-destructive measurement can reduce analysis time. This is especially important when quantification of multiple APIs is required for tests such as content uniformity, assay and ID...
news
Celltrion to develop assay for evidence-based decision-making in anti-TNF treatment
5 July 2016 | By Victoria White, Digital Content Producer
Celltrion is to develop laboratory tests that will enable physicians to identify when patients on an anti-TNF drug require a change of dose...
news
DiscoverX launches KILR™ assay platform for use in cancer immunotherapy drug development
30 March 2016 | By DiscoverX Corporation
DiscoverX Corporation has launched the KILR Retroparticles product line, providing scientists complete flexibility to develop a simple cytotoxicity assay in almost any cell line...
news
Easily measure cancer cell death in a co-culture with KILR™ Assays from DiscoverX
2 February 2016 | By DiscoverX
DiscoverX Corporation announced the launch of the KILR Cytotoxicity Assay, a pioneering approach to accelerate the development of cancer immunotherapy drugs...
